个人中心 - 老虎社区

Syracuse

IP属地：未知

帖子 · 1帖子 · 1
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- SyracuseSyracuse
  ·2021-12-02
  To the moon
  Glaxo and Vir Biotechnology stocks climbed in premarket trading<blockquote>葛兰素史克和 Vir Biotechnology 股票在盘前交易中上涨</blockquote>
  Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effecti
  Glaxo and Vir Biotechnology stocks climbed in premarket trading<blockquote>葛兰素史克和 Vir Biotechnology 股票在盘前交易中上涨</blockquote>
  1,805 评论
  4
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3570889929256934","uuid":"3570889929256934","gmtCreate":1607796541185,"gmtModify":1638438003317,"name":"Syracuse","pinyin":"syracuse","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/decb32057fdbb92949b236b3b432eef4","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":5,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.06.07","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.74%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.23","exceedPercentage":"93.91%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":603431767,"gmtCreate":1638437370596,"gmtModify":1638437730928,"author":{"id":"3570889929256934","authorId":"3570889929256934","name":"Syracuse","avatar":"https://static.tigerbbs.com/decb32057fdbb92949b236b3b432eef4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570889929256934","idStr":"3570889929256934"},"themes":[],"title":"","htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603431767","repostId":"1133804924","repostType":2,"repost":{"id":"1133804924","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638436562,"share":"https://www.laohunote.com/m/news/1133804924?lang=zh_CN&edition=full","pubTime":"2021-12-02 17:16","market":"us","language":"en","title":"Glaxo and Vir Biotechnology stocks climbed in premarket trading<blockquote>葛兰素史克和 Vir Biotechnology 股票在盘前交易中上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1133804924","media":"Tiger Newspress","summary":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effecti","content":"<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p><p><blockquote>早期测试显示，由于葛兰素新冠抗体药物对奥密克戎有效，葛兰素史克和 Vir Biotechnology 的股票在盘前交易中攀升。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p><p><blockquote>据葛兰素史克公司称，该公司的 Covid-19 抗体疗法在早期测试中似乎对新的奥密克戎变种有效。</blockquote></p><p> Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p><p><blockquote>葛兰素史克周四在一份声明中表示，对该变种中发现的突变的实验室测试表明，该药物对该病毒仍然有效。该制药商目前正在进行体外测试，以确认对所有奥密克戎突变组合的反应，并计划在年底前提供更新。</blockquote></p><p> Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p><p><blockquote>葛兰素史克对名为 sotrovimab 的药物发表评论之际，人们不确定奥密克戎会在多大程度上削弱现有药物和疫苗的防御能力。再生元制药公司本周早些时候表示，在早期证据表明其自己的抗体可能效果较差后，该公司正在进行进一步的测试。</blockquote></p><p> “Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p><p><blockquote>“联合开发商 Vir Biotechnology Inc. 的首席执行官 George Scangos 说：”Sotrovimab 是在特意设计时考虑到了一种变异病毒。“这个假设一次又一次地被证实。”</blockquote></p><p> The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p><p><blockquote>英国监管机构周四也批准了该药物的使用，此前该药物在试验中降低了轻度至中度 Covid-19 患者的住院和死亡风险。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo and Vir Biotechnology stocks climbed in premarket trading<blockquote>葛兰素史克和 Vir Biotechnology 股票在盘前交易中上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo and Vir Biotechnology stocks climbed in premarket trading<blockquote>葛兰素史克和 Vir Biotechnology 股票在盘前交易中上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-02 17:16</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Glaxo and Vir Biotechnology stocks climbed in premarket trading&nbsp;as&nbsp;Glaxo covid antibody drug effective on Omicron, early tests showed.</p><p><blockquote>早期测试显示，由于葛兰素新冠抗体药物对奥密克戎有效，葛兰素史克和 Vir Biotechnology 的股票在盘前交易中攀升。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/253355c4cd31265752c32735b1c81c77\" tg-width=\"853\" tg-height=\"620\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/a15f1091bcfaf0898519bf6c6ef79efe\" tg-width=\"853\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> GlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.</p><p><blockquote>据葛兰素史克公司称，该公司的 Covid-19 抗体疗法在早期测试中似乎对新的奥密克戎变种有效。</blockquote></p><p> Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a&nbsp;statement&nbsp;Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.</p><p><blockquote>葛兰素史克周四在一份声明中表示，对该变种中发现的突变的实验室测试表明，该药物对该病毒仍然有效。该制药商目前正在进行体外测试，以确认对所有奥密克戎突变组合的反应，并计划在年底前提供更新。</blockquote></p><p> Glaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.</p><p><blockquote>葛兰素史克对名为 sotrovimab 的药物发表评论之际，人们不确定奥密克戎会在多大程度上削弱现有药物和疫苗的防御能力。再生元制药公司本周早些时候表示，在早期证据表明其自己的抗体可能效果较差后，该公司正在进行进一步的测试。</blockquote></p><p> “Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”</p><p><blockquote>“联合开发商 Vir Biotechnology Inc. 的首席执行官 George Scangos 说：”Sotrovimab 是在特意设计时考虑到了一种变异病毒。“这个假设一次又一次地被证实。”</blockquote></p><p> The U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.</p><p><blockquote>英国监管机构周四也批准了该药物的使用，此前该药物在试验中降低了轻度至中度 Covid-19 患者的住院和死亡风险。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133804924","content_text":"Glaxo and Vir Biotechnology stocks climbed in premarket trading as Glaxo covid antibody drug effective on Omicron, early tests showed.\n\nGlaxoSmithKline Plc’s Covid-19 antibody treatment looks to be effective against the new omicron variant in early testing, according to the company.\nLab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a statement Thursday. The drugmaker is now conducting in vitro testing to confirm the response against a combination of all the omicron mutations and plans to give an update by year-end.\nGlaxo’s comments on the drug known as sotrovimab come amid uncertainty about how much omicron erodes the defenses of existing medicines and vaccines. Regeneron Pharmaceuticals Inc. earlier this week said it was conducting further testing after early evidence suggested that its own antibody may be less effective.\n“Sotrovimab was deliberately designed with a mutating virus in mind,” said George Scangos, chief executive officer of co-developer Vir Biotechnology Inc. “This hypothesis has borne out again and again.”\nThe U.K. regulator also authorized for drug for use Thursday, after it reduced the risk of hospitalization and death in people with mild to moderate Covid-19 in trials.","news_type":1,"symbols_score_info":{"VIR":0.9,"GSK":0.9}},"isVote":1,"tweetType":1,"viewCount":1805,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}